[go: up one dir, main page]

WO2007014514A1 - Utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de peau - Google Patents

Utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de peau Download PDF

Info

Publication number
WO2007014514A1
WO2007014514A1 PCT/CN2006/001791 CN2006001791W WO2007014514A1 WO 2007014514 A1 WO2007014514 A1 WO 2007014514A1 CN 2006001791 W CN2006001791 W CN 2006001791W WO 2007014514 A1 WO2007014514 A1 WO 2007014514A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
preparation
medicament
skin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2006/001791
Other languages
English (en)
Chinese (zh)
Inventor
Weihua Qin
Qingmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenghua Guangzhou Pharmaceutical Science and Tech Co Ltd
Original Assignee
Shenghua Guangzhou Pharmaceutical Science and Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenghua Guangzhou Pharmaceutical Science and Tech Co Ltd filed Critical Shenghua Guangzhou Pharmaceutical Science and Tech Co Ltd
Publication of WO2007014514A1 publication Critical patent/WO2007014514A1/fr
Priority to US12/024,833 priority Critical patent/US8044098B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Definitions

  • HPV16, 18 of granular or mastoid erosion was significantly different from that of normal cervix.
  • the positive rate of HPV16 and 18 in cervical cancer was 83.33%.
  • the high-risk HPV DNA was integrated into the host cell chromosome, which produced E6 and E7 tumor proteins, which inhibited the tumor suppressor genes p53 and Rb, respectively, and enabled the cells to escape p53 and The control of Rb leads to abnormal cell cycle control, which makes the cells that are usually at rest active and tumors grow. If HPV16 persists, cervical lesions can develop. Unlike vulvar infection, cervical HPV infection is mainly HPV16/18 type, often without phlegm change, but long-term existence of recessive infection, first causing dysplasia, causing cancer when other factors are involved.
  • Herpes simplex virus is a double-stranded DNA virus that invades the body through various routes such as the oral cavity, respiratory tract, genital tract mucosa, and damaged skin. Human infection is very common, and the infection rate is 80-90%. The common clinical manifestation is herpes accumulation in the mucous membrane or skin. Occasionally, serious systemic diseases can occur, involving the internal organs. Studies have shown that HSV-1 and HSV-2 may be associated with lip, vulvar and cervical cancer, respectively, and have received attention (Sun He et al., Chinese Journal of Practical Gynecology and Obstetrics, 2001, 17 ( 7 ): 407-409 ). The current treatments include herpes simplex, cytarabine, adenosine, vinyl bromide and acyclovir, but the treatment takes a long time and takes 5 to 7 days. Summary of the invention
  • the main main material materials used in the invention (both content content is greater than 9999%%) and its source source--..
  • HPV virus source Specimens of condyloma acuminata from clinical standards of multiple patients. After excision, wash the blood with physiological saline. Under sterile conditions, cut the specimen, add 3 times volume of physiological saline, mix and grind to homogenate and place at -40 °C. spare.
  • the homogenized condyloma acuminata tissue was homogenized 50 ⁇ 1, grouped as shown in Table 1, and 50 ⁇ l each of the test drug solution was added. Incubate at 37 °C for 24 hours, then perform the assay according to the HPV6, 11 and 16, 18 FQ-PCR diagnostic kits purchased from Daan Gene Diagnostic Center: 0.2ml of DNA extracted by conventional alkaline lysis In the wall reaction tube, a certain concentration of primers, F-PROBE, DNTP, DNA polymerase and buffer were added at the same time, and then ABI PRISMTM 7700 real-time PCR amplification instrument was used to denature at 93 ° C for 2 min, followed by 93 ° C for 45 s. At 55 °C for 120 s, 40 cycles were repeated. The quantitative results were automatically analyzed by computer software to calculate the quantitative results of the initial copy number. The data is shown in Table 1.
  • Example 1 Preparation of gallic acid microemulsion disinfectant, 22 patients with clinical diagnosis of herpes simplex virus (HSV) infection, randomly divided into gallic acid microemulsion disinfectant group and acyclovir ointment group, each group of 11 people, Apply three times per sputum and apply the affected area to the affected area. The results showed that the average recovery time was 3 days in the gallic acid disinfectant group and 5.5 days in the acyclovir ointment group. There was a significant difference between the two groups. The effect of the gallic acid disinfectant group was better than that of the acyclovir ointment group.
  • HSV herpes simplex virus
  • the p-hydroxybenzoic acid and the analog thereof of the invention can be used for preparing a medicament for preventing and treating viral infection of skin mucosa, in particular for preparing a medicament for preventing and treating human papillomavirus and herpes virus infection, Such as genital warts, vaginitis, cervicitis or cervical erosion.
  • the compounds of the invention have the ability to rapidly and efficiently kill sharp prions in vitro.
  • P-hydroxybenzoic acid and its analogs are formulated into various pharmaceutical or personal care products in combination with various excipients for dermatological use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l’utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de la peau et d’une infection par le virus de l’herpès, dans laquelle l’infection virale comprend le condylome acuminé, la vaginite, la cervicite, et l’érosion cervicale. D’autre part, l’invention concerne également les divers types de médicaments et de produits de soin personnels préparés à base d’acide p-hydroxybenzoïque et d’analogues et des adjuvants pour une administration par la peau.
PCT/CN2006/001791 2005-08-02 2006-07-21 Utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de peau Ceased WO2007014514A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/024,833 US8044098B2 (en) 2005-08-02 2008-02-01 Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100122885A CN100428930C (zh) 2005-08-02 2005-08-02 对羟基苯甲酸及其类似物在制备预防和治疗皮肤黏膜病毒性感染药物中的应用
CN200510012288.5 2005-08-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2006/001792 Continuation-In-Part WO2007014515A1 (fr) 2005-08-02 2006-07-21 Utilisation d’ester d’acide hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’infection virale
US12/024,833 Continuation-In-Part US8044098B2 (en) 2005-08-02 2008-02-01 Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection

Publications (1)

Publication Number Publication Date
WO2007014514A1 true WO2007014514A1 (fr) 2007-02-08

Family

ID=37698613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001791 Ceased WO2007014514A1 (fr) 2005-08-02 2006-07-21 Utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de peau

Country Status (2)

Country Link
CN (1) CN100428930C (fr)
WO (1) WO2007014514A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292329A1 (en) * 2007-06-20 2010-11-18 Roy Arlington Jordan 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106474142A (zh) * 2016-08-28 2017-03-08 贺秀平 一种治疗宫颈白斑并预防并发症的口服制剂及其制备方法
CN107929384A (zh) * 2017-11-28 2018-04-20 辽宁大学 黑树莓提取物在制备治疗宫颈炎、宫颈糜烂药物中的应用
CN108498557A (zh) * 2018-07-05 2018-09-07 周长征 鬼箭羽抗hsv-1病毒的有效部位和制备方法
CN109620820B (zh) * 2019-01-30 2021-03-30 桂林医学院 对羟基苯甲酸在制备治疗炎症性肠病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1167567A (zh) * 1996-06-07 1997-12-17 菱田岩 杀菌、抗菌和抑菌组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1167567A (zh) * 1996-06-07 1997-12-17 菱田岩 杀菌、抗菌和抑菌组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KANE C.-J. ET AL.: "Methyl gallate, methyl-3,4,5-trihydroxybenzoate, is a potent and highly specific inhibitor of herpes simplex virus in vitro. II. Antiviral activity of methyl gallate and its derivatives", BIOSCI.-REP., vol. 8, no. 1, February 1988 (1988-02-01), pages 95 - 102, XP003008356, DOI: doi:10.1007/BF01128976 *
LI X. ET AL.: "Research of biology effect of gallic acid", CHINA PHARMACIST, vol. 7, no. 10, 2004, pages 767 - 769, XP008076953 *
SUN H. ET AL.: "Study on the relationship between the cervical erosion and the herpes simplex virus infection in Xinjiang Uighur and Han nationality women", ZHONGGUO SHIYONG FUKEYUCHANKE ZAZHI, vol. 17, no. 7, July 2001 (2001-07-01), pages 407 - 409, XP008077240 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292329A1 (en) * 2007-06-20 2010-11-18 Roy Arlington Jordan 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain
US8785504B2 (en) * 2007-06-20 2014-07-22 Roy Arlington Jordan 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain

Also Published As

Publication number Publication date
CN1907275A (zh) 2007-02-07
CN100428930C (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
EP1079802B1 (fr) Compositions de prevention ou traitement de maladies affectant les muqueuses ou la peau, ou de contraception
CN100427082C (zh) 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
RU2760457C1 (ru) Хлорохин-гель, способ его изготовления и применения
CN102908611A (zh) 一种预防和控制人乳头瘤病毒感染的生物蛋白敷料及隐形膜
CN102670588A (zh) 鞣花酸用于制备抗病毒药物的应用
WO2007014514A1 (fr) Utilisation d’acide p-hydroxybenzoïque et d’analogues pour la fabrication d’un médicament pour la prévention et le traitement d’une infection virale d’une muqueuse de peau
US7780992B2 (en) Antiviral medicament
CN101342166B (zh) 羟基苯甲酸酯及其类似物在制备预防和治疗乙型肝炎病毒的药物中的应用
US20040191311A1 (en) Use of methyltestosterone as a drug for treatment of human papilloma virus infections
US8044098B2 (en) Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection
WO2020143397A1 (fr) Utilisation d'un squelette de paroi cellulaire de nocardia rubra dans le traitement d'un ulcère aphteux récurrent
CN114652741B (zh) 一种用于抑制hpv的组合物、制剂及其应用
EP3241555A1 (fr) Utilisation d'analogues de l'ion pyrophosphate pour le traitement de l'infection par vph
Campoli Proactive sinecatechins for the treatment of cutaneous HPV related lesions
EP4046646A1 (fr) Compositions pharmaceutiques pour le traitement des infections par le hpv
HK1113747B (en) Use of hydroxybenzoic acid ester compounds for the manufacture of a medicament for the prevention and treatment of hpv infection
CN102697756B (zh) 香叶醇在制备治疗阴道炎的药物中的用途
CN101301299A (zh) 药物组合物及其在制备抗微生物药物中的应用
De Rosa et al. Research Article Effect of Immunomodulatory Supplements Based on Echinacea Angustifolia and Echinacea Purpurea on the Posttreatment Relapse Incidence of Genital Condylomatosis: A Prospective Randomized Study
WO2021155795A1 (fr) Composition pharmaceutique et son utilisation
HK1037861B (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
CN103893280A (zh) 拳参提取物在制备抗病毒药物中的应用及其提取方法
NZ527295A (en) Applicator for delivering a liquid or semi-solid topical formulation into a mucosal cavity, for example, a vagina

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12024833

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 12024833

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 06761526

Country of ref document: EP

Kind code of ref document: A1